NCT07383506
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07383506
Title A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Cogent Biosciences, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
HonorHealth Research Institute RECRUITING Scottsdale Arizona 85258 United States Details
START Los Angeles RECRUITING Los Angeles California 90025 United States Details
Sarah Cannon Research Institute (SCRI) at HealthONE-Denver RECRUITING Denver Colorado 80218 United States Details
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. RECRUITING Tampa Florida 33612 United States Details
Dana-Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
Washington University School of Medicine - Siteman Cancer Center RECRUITING St Louis Missouri 63110 United States Details
START New Jersey, LLC RECRUITING East Brunswick New Jersey 08816 United States Details
SCRI Oncology Partners - Nashville RECRUITING Nashville Tennessee 01071 United States Details
NEXT Austin RECRUITING Austin Texas 78758 United States Details
START Mountain Region, LLC RECRUITING West Valley City Utah 84119 United States Details
NEXT Virginia RECRUITING Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field